Navigation Links
Inovio Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
Date:3/17/2011

e study, which is being conducted by the U.S. Military HIV Research Program (MHRP) through its clinical research network in the U.S. and east Africa.

The company launched a U.S. Phase I clinical trial to evaluate its SynCon™ H5N1 (avian) influenza DNA vaccine, VGX-3400X, using intramuscular electroporation delivery. This H5N1 vaccine study represents the first step in demonstrating Inovio's novel universal influenza vaccine approach, which aims to bypass the current requirement for annual strain and subtype-specific influenza vaccines by developing a single vaccine to potentially protect against all strains within multiple targeted subtypes, such as H5N1 and H1N1, posing risk to humans. Inovio's affiliate, VGX International, also initiated a phase I clinical study of this vaccine candidate in Korea.

Subsequent to year end, Inovio's collaborator the University of Southampton initiated a Phase 2 clinical trial (WIN Trial) to treat leukemia utilizing Inovio's new ELGEN 1000 automated vaccine delivery device. This open-label, multi-center clinical trial is evaluating a DNA vaccine to treat chronic myeloid leukemia and acute myeloid leukemia.

Another partner, ChronTech Pharma AB, initiated a Phase IIb clinical study of its ChronVac-C® DNA vaccine for hepatitis C virus (HCV) delivered by Inovio's proprietary electroporation DNA vaccine delivery technology in combination with standard of care. In a Phase I clinical trial of ChronVac-C using Inovio's MedPulser® electroporation device the therapy resulted in a robust increase in T-cell immune responses against HCV and was safe and well-tolerated. Post-study observation of subjects who completed the protocol and then entered into standard of care (SOC) treatment using interferon and ribavirin showed a complete and rapid viral response (four weeks) in 70% of those participants (5 of 7 patients). More significantly, 83% of the participants (5 of 6 patients) who were monitored for an exten
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
2. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
3. Inovio Pharmaceuticals Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovios Electroporation Delivery Technology
4. Inovio Pharmaceuticals to Present at ROTH 23rd Annual Growth Stock Conference
5. Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
6. Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences
7. Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery
8. Inovio Pharmaceuticals Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial
9. University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
10. Inovio Pharmaceuticals Closes $24.3 Million Registered Offering
11. Akrimax Pharmaceuticals, LLC, Introduces NitroMist® (Nitroglycerin Lingual Aerosol) 400mcg/Spray
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... NEW YORK , June 18, 2013 ... BDX ) are accelerating the development of new products that ... a new collaboration announced today. This new, three-year commitment is ... diabetes (T1D). Many patients with T1D not only ... catheter to be placed in the body for a number ...
(Date:6/18/2013)... LAKE CITY , June 18, 2013 /PRNewswire/ ... informatics products for healthcare and life sciences research, ... General Services Administration (GSA) IT Schedule 70 supply ... now certified to provide innovative IT solutions to ... In accordance with this contract, Remedy has placed ...
(Date:6/18/2013)... 18, 2013  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ... will present a general corporate update in conjunction with its ... June 25 at 2:10 p.m. Pacific Time in ... meeting is as follows: 2:00 p.m. – 2:10 p.m. Annual ... April 26, 2013) 2:10 p.m. – 3:15 p.m. Corporate Presentation ...
Breaking Medicine Technology:JDRF Extends Collaboration with BD to Develop Combined Infusion and Monitoring Products for People with Type 1 Diabetes 2JDRF Extends Collaboration with BD to Develop Combined Infusion and Monitoring Products for People with Type 1 Diabetes 3Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 2Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 3Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 4Isis Pharmaceuticals to Present a General Corporate Update at its 2013 Annual Meeting of Stockholders and Open House 2
(Date:6/18/2013)... a much different and more complex metabolism ... Texas at Dallas have found that exploiting these differences ... , In an article published online May 21 in ... compared the metabolic characteristics of non-small-cell lung cancer cells ... , They found that the cancer cells consumed ...
(Date:6/18/2013)... More than 1.1 million people in the U.S. ages ... Centers for Disease Control and Prevention (CDC). Of those, nearly ... National HIV Testing Day on June 27, Allsup, a nationwide ... the CDC and other organizations are raising awareness of the ... 50,000 new HIV infections each year. Along with developing AIDS, ...
(Date:6/18/2013)... Two months ago, Suyima Torres, 28, died from respiratory ... of a silicone treatment for gluteus augmentation at Cuerpos Health ... by a mystery Venezuelan doctor in a center that was ... Vazquez of Bayshore Cosmetic Surgery , women suffering from ... not board certified is more common than people think. ...
(Date:6/18/2013)... As Mirena lawsuit claims continue ... new report has revealed that that the IUD has been ... Administration (FDA) adverse event reports since coming on the market ... 4.700 Mirena users have reported device dislocation or migration to ... experienced uterine perforations due to Mirena.* , “We are not ...
(Date:6/18/2013)... Lauren Sciences, a privately-held biotechnology company furthering development ... today that it was independently recognized as a ... Platform, and selected as a Featured Company, in ... , The report, " Early Stage Drug Delivery ... features companies MCD Group independently selected as technology ...
Breaking Medicine News(10 mins):Health News:UT Dallas study suggests new approach to fight lung cancer 2Health News:UT Dallas study suggests new approach to fight lung cancer 3Health News:Allsup Observes National HIV Testing Day June 27 2Health News:Allsup Observes National HIV Testing Day June 27 3Health News:Dr. Bernabe Vazquez Speaks on Miami Woman’s Deadly Silicone Butt Injection 2Health News:Dr. Bernabe Vazquez Speaks on Miami Woman’s Deadly Silicone Butt Injection 3Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Mounting Reports of Mirena Side Effects, Including Device Migration, Uterine Perforations 2Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Mounting Reports of Mirena Side Effects, Including Device Migration, Uterine Perforations 3
... Experts cite small but potential danger to the blood supply, but ... A U.S. Department of Health and Human Services panel of experts ... donating blood, while advocating for more research on the controversial issue. ... the early days of the AIDS crisis -- prevents any man ...
... for whom treatment will be ineffective , SATURDAY, ... with poor response to treatment for hepatitis C infection ... the DNA of 1,362 hepatitis C patients and pinpointed ... treatment. The variant occurs in a gene called IL28B, ...
... Coast medical centers, universities and public health institutions from ... to improve community disaster readiness and recovery through research ... The consortium, known as SECURE (Science, Education, ... a two-year, $4 million grant from the National Center ...
... of self-control, a University of Pennsylvania psychologist says the data ... is the resource used to manage self control and that ... The analysis, conducted by Robert Kurzban and published in the ... that evidence previously presented in favor of the claim that ...
... New York University,s Center for Neural Science, has been ... Award for his work on how the brain reconstructs ... the award with William T. Newsome, a Stanford University ... a $1.3 million prize, the largest monetary prize in ...
... health care and yet achieve near-universal coverage and often better ... repeatedly during the health reform debate, and yet the answers ... health care system? Population differences? These are some ... a new book co-authored by Hastings Center scholar Michael Gusmano ...
Cached Medicine News:Health News:U.S. Panel Upholds Ban on Gay Men as Blood Donors 2Health News:U.S. Panel Upholds Ban on Gay Men as Blood Donors 3Health News:Research alliance aims to help vulnerable communities cope with disaster 2Health News:Research alliance aims to help vulnerable communities cope with disaster 3Health News:Research alliance aims to help vulnerable communities cope with disaster 4Health News:University of Pennsylvania: Contrary to popular models, sugar is not burned by self-control tasks 2Health News:University of Pennsylvania: Contrary to popular models, sugar is not burned by self-control tasks 3Health News:NYU's Movshon receives Champalimaud Vision Award for work on how brain reconstructs images 2Health News:New book compares health care in New York, Paris and London 2
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
The chest access blanket is designed specifically for the thoracic surgery patient....
The full access underbody blanket is positioned on the procedure table before the patient arrives to the room....
The Bair Hugger outpatient blanket makes it easy to give your patients the benefit of prewarming and enhance patient comfort during outpatient procedures....
Medicine Products: